Verano Holdings VRNO
OTC VRNO
$6.09 +0.25 (+4.28%)
At close: Aug 19, 2026 · 3:58 PM UTC

Verano Holdings (VRNO) Liabilities and Shareholders Equity (2021 - 2026)

Verano Holdings (VRNO) posted quarterly Liabilities and Shareholders Equity of $1.7 billion for Q1 2026, down 13.24% year-over-year from $2.0 billion in Q1 2025, and down 1.91% quarter-over-quarter from $1.7 billion in Q4 2025.

Verano Holdings (VRNO) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity fell 13.24% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $7.3 billion (down 14.09% YoY), while the FY2025 annual figure was $1.7 billion, down 12.66% from the prior year.
  • Liabilities and Shareholders Equity retreated to $1.7 billion in Q1 2026 per VRNO's latest filing, from $1.7 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.6 billion in Q3 2022 and bottomed at $1.7 billion in Q1 2026.
  • Historically, Liabilities and Shareholders Equity has averaged $2.2 billion across 5 years, with a median of $2.3 billion in 2024.
  • Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity dropped 1.72% — and 2025, when it dropped 16.82%.
  • Verano Holdings' Liabilities and Shareholders Equity stood at $2.4 billion in 2022, then dropped by 3.23% to $2.3 billion in 2023, then decreased by 14.0% to $2.0 billion in 2024, then dropped by 12.66% to $1.7 billion in 2025, then dropped by 1.91% to $1.7 billion in 2026.
  • Business Quant data shows VRNO's Liabilities and Shareholders Equity at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.9 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 43.94 Bn 42.97 Bn - 43.71 Bn
2 Teva Pharmaceutical Industries 42.95 Bn 39.30 Bn 2.15 Bn 39.86 Bn
3 Zoetis 31.58 Bn 29.90 Bn 1.05 Bn 15.08 Bn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn 98.27 Bn
5 United Therapeutics 22.16 Bn 19.49 Bn 683.80 Mn 7.22 Bn
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn 35.04 Bn
7 Neurocrine Biosciences 15.53 Bn 15.14 Bn 935.80 Mn 5.36 Bn
8 Elanco Animal Health 11.76 Bn 11.23 Bn 798.00 Mn 13.56 Bn
9 Dr Reddys Laboratories 10.11 Bn 9.95 Bn - 6.18 Bn
10 Verano Holdings 438.82 Mn 353.62 Mn 99.70 Mn 1.70 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 1.70 Bn
Mar 31, 2026 1.71 Bn
Dec 31, 2025 1.74 Bn
Sep 30, 2025 1.93 Bn
Jun 30, 2025 1.94 Bn
Mar 31, 2025 1.97 Bn
Dec 31, 2024 1.99 Bn
Sep 30, 2024 2.31 Bn
Jun 30, 2024 2.24 Bn
Mar 31, 2024 2.32 Bn
Dec 31, 2023 2.32 Bn
Sep 30, 2023 2.36 Bn
Jun 30, 2023 2.35 Bn
Mar 31, 2023 2.37 Bn
Dec 31, 2022 2.40 Bn
Sep 30, 2022 2.62 Bn
Jun 30, 2022 2.60 Bn
Dec 31, 2021 2.55 Bn